8 results on '"Graham, Myfanwy"'
Search Results
2. Avoiding the Premature Introduction of Psychedelic Medicines in Alzheimer's Disease and Related Disorders.
- Author
-
Carter, Adrian, Graham, Myfanwy, Hall, Wayne, Barber, Michaela, and Gardner, John
- Subjects
- *
DRUG efficacy , *AMYLOID , *ANTIDEPRESSANTS , *DEEP brain stimulation , *ALZHEIMER'S disease , *ANTI-inflammatory agents , *ALKALOIDS , *SEROTONIN uptake inhibitors , *DEMENTIA , *MENTAL depression , *ANXIETY , *ECSTASY (Drug) , *HALLUCINOGENIC drugs - Published
- 2023
- Full Text
- View/download PDF
3. NSW Cannabis Medicines Advisory Service preliminary survey results: enquirer perceptions and patient outcomes.
- Author
-
Graham, Myfanwy, Bird, Sonia, Howard, Zachary, Dobson, Michelle, Palazzi, Kerrin, Lucas, Catherine J., Schneider, Jennifer, Eagar, Kathy, and Martin, Jennifer H.
- Subjects
- *
DRUG efficacy , *PAIN , *SCIENTIFIC observation , *MEDICINE information services , *ATTITUDES of medical personnel , *ANALGESICS , *CROSS-sectional method , *HEALTH information services , *MEDICAL marijuana , *QUALITY assurance , *DESCRIPTIVE statistics , *DECISION making , *PHARMACY information services , *CANNABINOIDS , *MEDICAL prescriptions , *PAIN management , *THERAPEUTICS , *EVALUATION - Abstract
Background: In 2018, an innovative, State government‐funded cannabis medicines drug information service was established for health professionals in New South Wales (NSW). The NSW Cannabis Medicines Advisory Service (CMAS) provides expert clinical guidance and support to medical practitioners considering prescribing a cannabis medicine to their patient(s). Aims: This research examines quality assurance and patient outcomes related to enquirers' experience with NSW CMAS. Methods: Data collection involved an online, anonymous survey with two components. Following a health professional enquiry, quality assurance data were collected about the enquirers' experience with NSW CMAS. The second survey focussed on patient outcomes and provides real‐world observational data about cannabis medicines safety and effectiveness across a wide range of indications. Results: Data collection occurred between January 2020 and June 2021. Preliminary analyses were based on 68 quality assurance and 50 patient outcomes survey responses. General practitioners represented the highest proportion of survey responses (n = 33; 49%). The most common enquiry involved 'patient‐specific advice' (n = 50; 74%). Patient‐specific information provided by the service was mainly used for prescribing decision support (n = 45; 90%). Conclusions: Preliminary findings highlight the impact of an innovative cannabis medicines drug information service in supporting health professional clinical practice in an area of rapid knowledge translation. Quality assurance data indicate that the service is perceived well by the majority of enquirers. Patient outcomes data across a wide range of indications suggest some effectiveness and a reasonable safety profile for prescribed cannabis medicines for most patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. 'The wild west of medicine': A qualitative investigation of the factors influencing Australian health‐care practitioners' delivery of medicinal cannabis.
- Author
-
Dobson, Olivia, Barber, Michaela, Graham, Myfanwy, Carter, Adrian, and Savic, Michael
- Abstract
Introduction: Strong patient interest in the use of medicinal cannabis to treat various clinical indications has sparked global legislative changes. Practitioners are vital in implementing regulatory changes and facilitating patient access to medicinal cannabis, however, little is currently known about the factors influencing practitioners' uptake. Recent rapid increases in practitioner applications to prescribe medicinal cannabis in Australia provides a unique backdrop to examine the current factors influencing prescribing behaviours. This qualitative study examined Australian practitioners' perspectives on prescribing medicinal cannabis to provide a comprehensive exploration of the potential factors influencing uptake in clinical practice. Methods: Seventeen semi‐structured interviews were conducted with Australian health‐care practitioners. Transcripts were analysed using the Framework approach to thematic analysis and cross‐mapped to appropriate domains of the Theoretical Domains Framework. Results: We identified four themes related to the barriers and facilitators to prescribing medicinal cannabis: (i) clinical capabilities needed to prescribe; (ii) prescribing an unapproved therapeutic good; (iii) negative attitudes towards prescribers in the medical community; and (iv) divergent beliefs about clinical utility. Discussion and Conclusions: Practitioners face multiple pervasive barriers to prescribing medicinal cannabis. Beliefs about clinical utility appear to be highly influential in shaping prescribing behaviours. Moreover, our findings suggest that a medicinal cannabis 'specialisation' has emerged within the Australian medical community. Findings demonstrate that a range of complex and multifaceted factors influence practitioners' medicinal cannabis prescribing behaviours. We highlight several considerations for policy and practice to support safe and appropriate patient access to medicinal cannabis in this emerging area of clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. A provisional evaluation of Australia's medical cannabis program.
- Author
-
Graham, Myfanwy, Chiu, Vivian, Stjepanović, Daniel, and Hall, Wayne
- Subjects
- *
HEALTH services accessibility , *GOVERNMENT regulation , *HOSPITAL health promotion programs , *MEDICAL marijuana , *DRUG monitoring , *DRUG side effects , *OFF-label use (Drugs) , *PATIENT safety , *THERAPEUTICS - Abstract
In 2016, the Australian Government legislated to allow cannabis to be prescribed to patients as an unapproved medicine under the special access provisions of the Therapeutic Goods Act. This paper compares the Australian regulatory approach with other national approaches, outlines the main provisions of the Special Access Scheme for medical cannabis, describes how the program has evolved since 2017, includes an analysis of adverse events reported to the Therapeutic Goods Administration, and discusses the barriers that remain for patients who wish to access medical cannabis. It assesses how well the Australian program has addressed the challenges of providing patients with easier access to medical cannabis while ensuring that high-quality products are used safely and effectively under medical guidance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. From growers to patients: Multi-stakeholder views on the use of, and access to medicinal cannabis in Australia.
- Author
-
Erku, Daniel, Greenwood, Lisa-Marie, Graham, Myfanwy, Hallinan, Christine Mary, Bartschi, Jessica G., Renaud, Elianne, and Scuffham, Paul
- Subjects
- *
MEDICAL marijuana , *FARMERS , *CONSUMER activism , *PRESSURE groups , *MEDICAL personnel , *MARIJUANA industry - Abstract
Background: Patient interest in the use of cannabis-based medicines (CBMs) has increased in Australia. While recent policy and legislative changes have enabled health practitioners to prescribe CBMs for their patients, many patients still struggle to access CBMs. This paper employed a thematic analysis to submissions made to a 2019 Australian government inquiry into current barriers of patient access to medical cannabis. Methods: We identified 121 submissions from patients or family members (n = 63), government bodies (n = 5), non-government organisations (i.e., professional health bodies, charities, consumer organisations or advocacy groups; n = 25), medical cannabis and pharmaceutical industry (n = 16), and individual health professionals, academics, or research centres (n = 12). Data were coded using NVivo 12 software and thematically analysed. The findings were presented narratively using a modified Levesque's patient-centred access to care framework which includes: i) appropriateness; ii) availability and geographic accessibility; iii) acceptability; and iv) affordability. Results: Submissions from government agencies and professional health bodies consistently supported maintaining the current regulatory frameworks and access pathways, whereas an overwhelming majority of patients, advocacy groups and the medical cannabis industry described the current regulatory and access models as 'not fit for purpose'. These differing views seem to arise from divergent persepctives on (i) what and how much evidence is needed for policy and practice, and (ii) how patients should be given access to medical cannabis products amidst empirical uncertainty. Notwithstanding these differences, there were commonalities among some stakeholders regarding the various supply, regulatory, legislative, financial, and dispensing challenges that hindered timely access to CBMs. Conclusions: Progress in addressing the fundamental barriers that determine if and how a patient accesses and uses CBMs needs i) a 'system-level' reform that gives due consideration to the geographic disparity in access to prescribers and medical cannabis, and ii) reframing societal and health professional's views of CBMs by decoupling recreational vs medical cannabis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Expert advice for prescribing cannabis medicines for patients with epilepsy—drawn from the Australian clinical experience.
- Author
-
Lawson, John, O'Brien, Terry, Graham, Myfanwy, Renaud, Elianne, Jones, Dean, Freeman, Jeremy, Lawn, Nicholas, and Martin, Jennifer H.
- Subjects
- *
PEOPLE with epilepsy , *DRUG registration , *ADVICE , *DRUG interactions , *DRUGS , *CANNABINOIDS - Abstract
There is international interest for consensus advice for prescribers working in the field of drug resistant epilepsy intending to trial potential therapies that are nonregistered or off‐label. Cannabinoids are one such therapy. In 2017, the New South Wales State Government (Australia) set up a cannabinoid prescribing guidance service for a wide variety of indications, based on known pharmacology together with the relevant new literature as it became available. Increasing interest in cannabis medicines use outside this State over the following 5 years together with a paucity of registration‐standard clinical trials, lack of information around dosing issues, drug interactions and biological plausibility meant there remained a large unmet need for such advice. To address the unmet need in epilepsy, and until medicines were registered or regulator quality data were available, it was agreed to bring together a working group comprising paediatric and adult epilepsy specialists, clinical pharmacists., clinical pharmacologists and cannabis researchers from across Australia to develop interim consensus advice for prescribers. Although interim, this consensus advice addresses much of the current practice gap by providing an informed overview of the different cannabis medicines currently available for use in the treatment of epilepsy in paediatric and adult settings, with information on dose, drug interactions, toxicity, type of seizure and frequency of symptom relief. As such it supplements the limited evidence currently available from clinical trials with experience from front‐line practice. It is expected that this consensus advice will be updated as new evidence emerges and will provide guidance for a subsequent Guideline. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Over the counter low-dose cannabidiol: A viewpoint from the ACRE Capacity Building Group.
- Author
-
Hallinan, Christine Mary, Eden, Edward, Graham, Myfanwy, Greenwood, Lisa-Marie, Mills, Jessica, Popat, Amirali, Truong, Linda, and Bonomo, Yvonne
- Subjects
- *
CANNABIDIOL , *CANNABIS (Genus) , *CANNABINOIDS , *MEDICAL marijuana - Abstract
Amidst growing global acceptance of medicinal cannabinoids as a potential therapeutic interest in cannabidiol (CBD) is increasing. In Australia in 2020, a government inquiry examined the barriers that the public are experiencing in accessing medicinal cannabis. A number of recommendations to improve access were made. In response to these recommendations, the Australian therapeutics regulatory authority down-scheduled CBD from Prescription Only (Schedule 4) to Pharmacist Only (Schedule 3). As a group of early to mid-career researchers of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), we propose some considerations in relation to over-the-counter availability of CBD and opportunities to improve knowledge about its potential therapeutic benefits alongside its increased uptake. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.